Hemodialysis-Resistant Hypertension: Control with an Orally Active Inhibitor of Angiotensin-Converting Enzyme*
- 1 May 1979
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 48 (5), 869-871
- https://doi.org/10.1210/jcem-48-5-869
Abstract
In two patients with end stage renal disease and dialysis-resistant hypertension, the orally active inhibitor of angiotensin-converting enzyme, captopril(SQ14, 225; 2-d-methyl-3-mercaptopropranoyl-l-proline, dramatically lowered blood pressure both before and during dialysis. This agent holds promise as an alternate to bilateral nephrectomy in such patients.Keywords
This publication has 4 references indexed in Scilit:
- Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in ManNew England Journal of Medicine, 1978
- Accentuated Vascular and Endocrine Response to Sq 20881 in HypertensionNew England Journal of Medicine, 1977
- Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive AgentsScience, 1977
- A SPECIFIC ORALLY ACTIVE INHIBITOR OF ANGIOTENSIN-CONVERTING ENZYME IN MANThe Lancet, 1977